Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Adrenocortical Carcinoma Clinical Trial

Official title:

Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00457587
• Other study ID #: Wue-Immuno-ACC-83/05
• Status: Recruiting
• Start date: September 2005
• Est. completion date: December 2026

Study information

• Verified date: May 2024
• Source: University of Wuerzburg
• Contact: Martin Fassnacht, MD
• Phone: 49-931-201-36507
• Email: fassnacht_m[@]medizin.uni-wuerzburg.de
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 2026
• Est. primary completion date: December 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with histological proven adrenocortical carcinoma

• healthy persons as control group

• Life expectancy > 6 months

Exclusion Criteria:

• autoimmune diseases

• severe clinical condition

Related Conditions & MeSH terms

• Adrenocortical Carcinoma
• Carcinoma
• Cushing Syndrome
• Cushing's Syndrome

Locations

Country	Name	City	State
Germany	Dept. of Medicine I, University of Wuerzburg	Wuerzburg

Sponsors (2)

Lead Sponsor	Collaborator
University of Wuerzburg	Deutsche Krebshilfe e.V., Bonn (Germany)

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, Fassnacht M, Sbiera S. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020 May;8(1):e000469. doi: — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To find reasonable antigens for a vaccination therapy in ACC		day of blood sampling
Primary	To investigate the role of tumor-induced suppression in ACC		NA, in vitro study

External Links

•   Homepage Dept. of Endocrinology, U Wuerzburg